Selected article for: "disease severity and myocardial injury"
Author: Kang, Yu; Chen, Tiffany; Mui, David; Ferrari, Victor; Jagasia, Dinesh; Scherrer-Crosbie, Marielle; Chen, Yucheng; Han, Yuchi
Title: Cardiovascular manifestations and treatment considerations in covid-19
  • Cord-id: 5l513o55
  • Document date: 2020_4_30
    • ID: 5l513o55
    Snippet: Since its recognition in December 2019, covid-19 has rapidly spread globally causing a pandemic. Pre-existing comorbidities such as hypertension, diabetes, and cardiovascular disease are associated with a greater severity and higher fatality rate of covid-19. Furthermore, covid-19 contributes to cardiovascular complications, including acute myocardial injury as a result of acute coronary syndrome, myocarditis, stress-cardiomyopathy, arrhythmias, cardiogenic shock, and cardiac arrest. The cardiov
    Document: Since its recognition in December 2019, covid-19 has rapidly spread globally causing a pandemic. Pre-existing comorbidities such as hypertension, diabetes, and cardiovascular disease are associated with a greater severity and higher fatality rate of covid-19. Furthermore, covid-19 contributes to cardiovascular complications, including acute myocardial injury as a result of acute coronary syndrome, myocarditis, stress-cardiomyopathy, arrhythmias, cardiogenic shock, and cardiac arrest. The cardiovascular interactions of covid-19 have similarities to that of severe acute respiratory syndrome, Middle East respiratory syndrome and influenza. Specific cardiovascular considerations are also necessary in supportive treatment with anticoagulation, the continued use of renin-angiotensin-aldosterone system inhibitors, arrhythmia monitoring, immunosuppression or modulation, and mechanical circulatory support.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and acute coronary syndrome: 1
    • ace inhibitor and acute heart failure: 1
    • ace inhibitor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • ace inhibitor and low heparin: 1
    • ace inhibitor and low molecular weight heparin: 1
    • ace inhibitor and lung alveolar: 1
    • ace inhibitor and lung injury: 1, 2, 3, 4
    • acei ace inhibitor and acute respiratory syndrome: 1, 2, 3
    • acei ace inhibitor and lung injury: 1, 2
    • acs acute coronary syndrome and acute coronary syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • acs acute coronary syndrome and acute heart failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acs acute coronary syndrome and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acs acute coronary syndrome and additional study: 1
    • acs acute coronary syndrome and admission ml: 1
    • acs acute coronary syndrome and low mortality: 1, 2, 3, 4
    • acs acute coronary syndrome and magnetic resonance: 1, 2, 3
    • activate immune cell and acute respiratory syndrome: 1
    • active inflammation and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8
    • active inflammation and low heparin: 1